Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study-Reference-Cited by-同舟云学术

Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study

Published:2015-05-28 Issue:4 Volume:80 Page:727-739
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Weber-Schoendorfer Corinna¹,Oppermann Marc¹,Wacker Evelin¹,Bernard Nathalie²,Beghin Delphine³,Cuppers-Maarschalkerweerd Benedikte⁴,Richardson Jonathan L.⁵,Rothuizen Laura E.⁶,Pistelli Alessandra⁷,Malm Heli⁸,Eleftheriou Georgios⁹,Kennedy Debra¹⁰,Kadioglu Duman Mine¹¹,Meister Reinhard¹²,Schaefer Christof¹,

Affiliation:

1. Pharmakovigilanzzentrum Embryonaltoxikologie, Institut für Klinische Pharmakologie und Toxikologie; Charité Universitätsmedizin Berlin; Berlin Germany

2. Centre Régional de Pharmacovigilance; Hospices Civils de Lyon; Lyon France

3. Centre de Référence sur les Agents Tératogènes (CRAT); Hôpitaux Universitaires Est Parisien (APHP); Paris France

4. Teratology Information Service; MH ’s-Hertogenbosch; Netherlands

5. UK Teratology Information Service; Newcastle upon Tyne Hospitals NHS Foundation Trust & Newcastle University; Newcastle upon Tyne United Kingdom

6. Swiss Teratogen Information Service (STIS) and Division of Clinical Pharmacology; University Hospital; Lausanne Switzerland

7. Centro di Riferimento Regionale di Tossicologia Perinatale; Azienda Ospedaliero Universitaria Careggi; Firenze Italy

8. Teratology Information Service; HUSLAB and Helsinki University Central Hospital; Helsinki Finland

9. Poison Control Centre and Teratology Information Service; Hospital Papa Giovanni XXIII; Bergamo Italy

10. Mothersafe; Royal Hospital for Women; Randwick Australia

11. Department of Pharmacology; Karadeniz Technical University; Trabzon Turkey

12. Department of Mathematics; Beuth Hochschule für Technik Berlin (University of Applied Sciences); Berlin Germany

Funder

Bundesministerium für Gesundheit (German Health Ministry

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12642/fullpdf

Reference47 articles.

1. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review;Nielsen;BMC Med,2013

2. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD);Shivananda;Gut,1996

3. Anti-TNFalpha therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis;Narula;Inflamm Bowel Dis,2014

4. Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease;Cheent;J Crohns Colitis,2010

5. Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy;Chambers;Birth Defects Res A Clin Mol Teratol,2012

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor Necrosis Alpha (TNF-α) Antagonists Used in Chronic Inflammatory Rheumatic Diseases: Risks and their Minimization Measures;Current Drug Safety;2024-11

2. Rhekiss—The German Register for Child Wish and Pregnancies in Inflammatory Rheumatic Diseases;Pharmacoepidemiology and Drug Safety;2024-08

3. Safety of TNF-α inhibitors: A real-world study based on the US FDA Adverse Event Reporting System Database;Medicine;2024-07-19

4. Rational approach to the prescription of anti-rheumatic drugs in rheumatoid arthritis: a product leaflet-based strategy in Italy;Frontiers in Immunology;2024-06-24

5. Anti-tumor necrosis factor-α therapy may not be safe during pregnancy in women with inflammatory bowel disease: an updated meta-analysis and systematic review;BMC Pregnancy and Childbirth;2024-04-08